rest of clinical and immunological features were similar to previously described in other series.

References:

- [1] Amezcua Guerra LM. Overlap between systemic lupus erythematosus and rheumatoid arthritis: is it real or just an illusion? *J Rheumatol* 2009; 36: 4-6.
- [2] Li J, Wu H, Huang X, Xu D, Zheng W, Zhao Y, et al. Clinical analysis of 56 patients with rhupus syndrome: manifestations and comparisons with systemic lupus erythematosus. *Medicine* 2014; 93(10).
- [3] Simón JA, Granados J, Cabiedes J, Ruiz Morales J, Alcocer Varela J. Clinical and immunogenetic characterization of Mexican patients with rhupus. *Lupus* 2002; 11: 287-292.
- [4] Tani C, D'Aniello D, Delle Sedie A, Carli L, Cagnoni M, Possemato N, et al. Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. *Autoimmun Rev* 2013; 12: 537-541.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4972

AB1045

CLINICAL, ANALYTICAL AND RADIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS WITH SARCOIDOSIS.

I. Madroñal García¹, C. Aguilera Cros¹, L. Mendez Diaz¹. ¹Hospital Universitario Virgen del Rocío, Reumatología, Sevilla, Spain

Background: Sarcoidosis is a systemic disease whose etiology is unknown. It is characterized by the formation of granulomas in any tissue of the organism. Ganglionic, pulmonary and cutaneous involvement is the most prevalent.

Objectives:

1. Describe clinical characteristics of a cohort of patients with sarcoidosis diagnosed.
2. Define the association between the ACE's number at diagnosis, radiological lung stage, treatment and course of disease.
3. Evaluate if the extrapulmonary involvement is related to the course of the disease.

Methods: Descriptive retrospective study of patients with S diagnosis treated in our Hospital in 2019. Data were obtained by reviewing medical records. Chi-square tests and parametric tests have been used to establish the differences described in the objectives.

Results: 102 patients diagnosed with sarcoidosis have been included, (51% females) with an average age of 56±11 years. Suspected diagnosis at the onset of disease was S in 70.6% of patients, followed by suspected lymphoma (20.6%). The average time for the definitive diagnosis of S was 9.5 months. 70.6% of the patients had elevated ACE titles at the beginning. Regarding the clinical manifestations, 18.6% of the patients presented fever at the beginning and 66.7% extrathoracic clinical manifestations. 72.5% have lymph node adenopathies, and in 91% there is thoracic involvement (the most frequent pulmonary stage is stage II). A biopsy was performed in 84.3% of the patients, the lung biopsy being the most performed (52.3%). 88.2% of patients received corticosteroid treatment at the onset of the disease (currently under treatment with corticosteroids 37.3%). 50% of patients are treated with immunosuppressants, Methotrexate was the most used. 5 patients are treated with biological therapy (AntiTNF).

Regarding the course of the disease, 51% of the patients have a chronic course, 45.1% are in remission and 3.9% have suffered a relapse of the disease. In this study, no significant relationship was found between the ACE values at the onset of the disease, the pulmonary stage and the course of the disease.

According to our data, patients presenting with extrathoracic clinical manifestations need more frequently corticosteroid treatment ($p = 0.017$) and immunosuppressive treatment ($p = 0.001$) with respect to patients who do not have an extrathoracic clinic. In addition, patients with an extrathoracic clinic present more frequently a chronic course of the disease than those who do not ($p = 0.019$).

Conclusion: The results described in this study are similar to those found in the literature. The differences found can be explained because patients presenting with extrathoracic clinical manifestations have a more complicated management and need more treatment than those with only pulmonary involvement, even patients with radiological stage I do not usually need treatment, only surveillance.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6414

AB1046

JOINT MANIFESTATIONS IN A COHORT OF PATIENTS WITH SARCOIDOSIS IN A THIRD LEVEL HOSPITAL.

I. Madroñal García¹, C. Aguilera Cros¹, L. Mendez Diaz¹. ¹Hospital Universitario Virgen del Rocío, Reumatología, Sevilla, Spain

Background: Sarcoidosis (S) is a systemic granulomatous disease of unknown etiology, which most frequently affects the ganglion, lung and skin, although it can affect other organs, including the musculoskeletal system.

Objectives:

- Describe the clinical, analytical and radiological characteristics of patients diagnosed with S presenting joint manifestations.
- To assess the association between patients who have joint manifestations and the use of corticosteroids (C) and immunosuppressants (IS), with respect to those without joint involvement.

Methods: Retrospective descriptive study of patients with diagnosis of S with joint manifestations, treated in our Hospital from 2017 to 2019. Data were obtained by reviewing medical records. Chi square tests and Fisher's exact test have been performed to establish the differences described in the objectives.

Results: From a database of 102 patients with S, 18 presented joint manifestations (50% women), with a mean age of 57 ± 6 years. Of these patients, 4 (22.2%) had presented positive ANA. Regarding the clinic, 3 patients presented the association of polyarthritis and bilateral ankle swelling, 8 patients presented with polyarthritis, 3 monoarthritis and 4 patients presented bilateral ankle swelling. 61.1% had fever at the onset of the disease.

14 patients (77.8%) had high ACE values at the onset of the disease, without presenting significant differences with respect to all patients diagnosed with S who do not have joint involvement.

All patients received treatment with C and 10 patients (55.5%) needed an IS treatment, finding no differences with respect to patients who do not have joint involvement ($p=0.92$).

On the course of the disease, the majority of patients with joint involvement have a chronic course (72.2%). Nor were significant differences found when compared with patients who have no joint involvement ($p = 0.73$).

Conclusion: Patients with joint involvement in our study have been 17.6% (18), an approximate result to that described in the literature (over 10%), although our result may be increased by the fact that the patients who are followed in Rheumatology present or have presented joint involvement. No significant differences were found between patients with S who presented joint involvement and those who did not, with respect to the initial ACE values, treatment and disease course. Prospective, multicenter and larger sample studies are necessary to better understand these associations.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.6444

AB1047

IGG4-RELATED DISEASE PRESENTATION REQUIRES ADMISSION TO THE EMERGENCY DEPARTMENT IN THE MAJORITY OF CASES

G. Mancuso^{1,2}, E. Della Torre^{1,2}, M. Lanzillotta^{1,2}, G. A. Ramirez^{1,2}, L. Dagna^{1,2}.

¹Università Vita-Salute San Raffaele, Milano, Italy; ²San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milano, Italy

Background: IgG4-related disease (IgG4-RD) is generally considered a chronic fibro-inflammatory condition with insidious presentation and subclinical course. Our clinical experience, however, suggests that a sizable proportion of patients experience multiple accesses to the emergency department (ED), either at disease onset or during the disease course.

Objectives: In the present study we aimed (i) to assess the prevalence of acute manifestations of IgG4-RD at disease onset requiring referral to the ED, and (ii) to calculate the diagnostic delay from the initial acute presentation.

Methods: We revised our database and identified patients admitted to the ED because of symptoms lately attributed to IgG4-RD onset (Group 1) and those that were referred to our outpatient clinic without previous urgent manifestations (Group 2). Acute manifestations were clustered based on the anatomical district affected by IgG4-RD. Epidemiological, clinical, and serological features of Group 1 and Group 2 were compared.

Results: The study included 141 patients with IgG4-RD. 76 (54%) presented to the ED at disease onset. The most common clinical manifestations requiring admission to the ED were jaundice (53%), abdominal pain (41%), and fever (10%). Gastrointestinal involvement was the most frequent cause of referral to the ED (71% of cases), followed by involvement of the retroperitoneum (14.5%), and of the nervous system (6.6%). Pancreato-biliary involvement was significantly more frequent in Group 1. Head, neck, salivary and lacrimal gland involvement was more frequent in Group 2. The diagnostic delay was significantly shorter in Group 1 than in Group 2.

Conclusion: Clinical manifestations associated with IgG4-RD onset require referral to the ED in the majority of cases. This finding contrasts with the general view of IgG4-RD as a condition with non-acute presentation.